Summit Therapeutics Inc

SMMT

Equity

ISIN US86627T1088 / Valor 56903013

NASDAQ (2024-09-17)

USD 26.22-11.1%

Summit Therapeutics Inc
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Summit Therapeutics Inc. is a biopharmaceutical company specializing in oncology, dedicated to the discovery, development, and commercialization of innovative therapies aimed at addressing serious unmet medical needs. The company's primary focus is on improving the quality and potential duration of life for patients with challenging cancer diagnoses. Summit's lead candidate, ivonescimab (SMT112 in the U.S., Canada, Europe, and Japan; AK112 in China and Australia), is a novel bispecific antibody that combines immunotherapy and anti-angiogenesis effects. Currently, ivonescimab is undergoing two Phase III clinical trials in Summit's licensed territories and multiple Phase III trials in China, led by its discoverer, Akeso, Inc. Initially targeting non-small cell lung cancer (NSCLC), Summit plans to explore ivonescimab's potential in other solid tumors, leveraging promising data from ongoing studies.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results ():

Summarized from source with an LLMView Source

Key figures

1,302%1Y

311%3Y

%5Y

Performance

171%1Y

154%3Y

140%5Y

Volatility